Search results :

Topotecan

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01XX17

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 27 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Leukopenia Leukopenia very common, 91% - 97% x x x x x x x x x x x x x x x x x x
Alopecia Alopecia very common, 0% - 54% x x x x x x x x x x x x x x x x x x x
Anaemia Anaemia very common, 1.9% - 98% x x x x x x x x x x x x x x x x x x x x
Neutropenia Neutropenia very common, 1% - 97% x x x x x x x x x x x x x x x x x x x x
Body temperature increased Body temperature increased very common, 0% - 43% x x x x x x x x x x x x x x x x x x x x
Colitis Colitis very common x x x
Infection Infection very common, 0% - 43% x x x x x x x x x x x x x x x x x x x
Thrombocytopenia Thrombocytopenia postmarketing — 0.5% - 81% x x x x x x x x x x x x x x x x x x x x
Thrombocytopenia aggravated x x x
Mucosal inflammation Mucosal inflammation very common, 14% x x x x
Febrile neutropenia Febrile neutropenia very common, 0% - 28% x x x x x x x x x x x x x x x
Mediastinal disorder Mediastinal disorder 5% - 14% x x x x x x x x x x x x x x x
Nausea Nausea very common, 0% - 64% x x x x x x x x x x x x x x x x x x x
Asthenia Fatigue very common, 0% - 29% x x x x x x x x x x x x x x x x x x x
Asthenia very common, 0% - 25% x x x x x x x x x x x x x x x x x x
Fatigue Fatigue very common, 0% - 29% x x x x x x x x x x x x x x x x x x x
Pneumonia Pneumonia 2% - 8% x x x x x x x x x x x
Dizziness Dizziness common x x
Dyspnoea Dyspnoea common, 1% - 22% x x x x x x x x x x x x x x
Pain Pain 1% - 50% x x x x x x x x x x x x
Pancytopenia Pancytopenia common x x x x x x x
Myelosuppression x x x x x x x x
Paraesthesia Paraesthesia common x x x x x x x x x x x x x
Alanine aminotransferase increased Alanine aminotransferase increased common x x x x
Sepsis Sepsis common, 0% - 43% x x x x x x x x x x x x x x x x x x
Infestation Infestation NOS 2% - 43% x x x x x x x x x x x x x x x
Intestinal obstruction Intestinal obstruction 0.8% - 5% x x x x x x
Vomiting Vomiting very common, 0% - 45% x x x x x x x x x x x x x x x x x x x
Diarrhoea Diarrhoea very common, 0% - 32% x x x x x x x x x x x x x x x x x x x
Malaise Malaise common, 0.3% - 5% x x x x x x x x x x x
Discomfort Malaise common, 0.3% - 5% x x x x x x x x x x x
Feeling abnormal Malaise common, 0.3% - 5% x x x x x x x x x x x
Ill-defined disorder Malaise common, 0.3% - 5% x x x x x x x x x x x
Abdominal pain Abdominal pain postmarketing — 1% - 22% x x x x x x x x x x x x x x x x x x
Gastrointestinal pain Abdominal pain postmarketing — 1% - 22% x x x x x x x x x x x x x x x x x x
Decreased appetite Anorexia very common, 0% - 19% x x x x x x x x x x x x x x x x x x x
Constipation Constipation very common, 0% - 29% x x x x x x x x x x x x x x x x x x
Malnutrition Malnutrition 1% - 19% x x x x x x x x x x x x x x x
Myalgia Myalgia 0% - 4% x x x x x x
Musculoskeletal discomfort Myalgia 0% - 4% x x x x x x
Arthralgia 0.2% - 3% x x x x x x
Cough Cough 0% - 15% x x x x x x x x x x x x x x
Dermatitis Rash common, 0% - 16% x x x x x x x x x x x x x x x x x x
Dermatitis postmarketing x x x x x x x x x x x
Rash Rash common, 0% - 16% x x x x x x x x x x x x x x x x x x
Headache Headache common, 0% - 18% x x x x x x x x x x x x x x
Hyperbilirubinaemia Hyperbilirubinaemia common, 0.8% - 1% x x x x x x x
Nervous system disorder Nervous system disorder 1% - 18% x x x x x x x x x
Arthralgia Arthralgia 0.2% - 3% x x x x x x
Chest pain Chest pain 0.3% - 2% x x x x x
Hypersensitivity Hypersensitivity common, 0% - 6% x x x x x x x x x x x x x x
Neuropathy peripheral Neuropathy uncommon, 0% - 30% x x x x x x x x x x x
Neuropathy peripheral uncommon x x
Hypoaesthesia Hypoaesthesia uncommon x x
Paresis Paresis uncommon x x
Haemorrhage Haemorrhage postmarketing — 1% - 14% x x x x x x x x x x x x x x x x x
Haemoglobin Haemorrhage postmarketing — 1% - 14% x x x x x x x x x x x x x x x x x
Stomatitis Stomatitis very common, 0% - 18% x x x x x x x x x x x x x x
Anaphylactic shock Anaphylactic shock rare x x x x
Anaphylactoid reaction postmarketing x x x x x x x x x x x
Angioedema Angioedema postmarketing, rare x x x x x x x x x x x x x x x
Extravasation Extravasation very rare, postmarketing x x x x x x x x x x x x x x
Gastrointestinal disorder Gastrointestinal disorder postmarketing — 4% - 6% x x x x x x x x x x x x x x x
Immune system disorder Immune system disorder postmarketing x x x x x x x x x x x x x x x
Lung disorder Lung disorder postmarketing x x x x x x x x
Pruritus Pruritus postmarketing, common x x x x x x x x x x x x x x x
Urticaria Urticaria rare x x x x x x x x x
Skin disorder Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x x x x x x x x x x
Interstitial lung disease Interstitial lung disease postmarketing, rare x x x x x x x x x x x x x x x x
Anaphylactoid reaction Anaphylactoid reaction postmarketing x x x x x x x x x x x
Neutropenic colitis Neutropenic colitis postmarketing, very common x x x x x x x x x x x x x x x x
Back pain Back pain x x x x x x
Pleuritic pain Pleuritic pain x x x
Dysmenorrhoea Dysmenorrhoea x x x
Ear pain Ear pain x x x
Epistaxis Epistaxis x x
Cardiac arrest Cardiac arrest x x x
Dyspepsia Heartburn x x x
Lethargy Lethargy x x x
Muscle spasms Cramp muscle x x x
Neoplasm Neoplasm x x x x
Neuralgia Neuralgia x x x
Pelvic pain Pelvic pain x x x
Pharyngitis Pharyngitis 0% - 1% x x x x x x x x x x
Pleural effusion Pleural effusion x x x
Pulmonary embolism Pulmonary embolism x x x
Acute respiratory distress syndrome Acute respiratory distress syndrome x x x
Rhinitis Rhinitis x x
Hyperhidrosis Sweating x x x
Angiopathy Angiopathy x x x x x x x x
Weight increased Weight increased x x x
Chills Chills x x x
Rigors x x x
Acute leukaemia Acute leukaemia x
Bone pain Bone pain x x x x x x x
Aspartate aminotransferase increased Aspartate aminotransferase increased x x
Rash erythematous Rash erythematous x x x x x
Dermatitis bullous Bullous eruption x x x x x
Lung neoplasm malignant Lung neoplasm malignant x
Hepatobiliary disease Hepatobiliary disease x x x x x x x x x x x x x x x
Blood bilirubin increased Blood bilirubin increased x x x x x x x x x x x
Rash maculo-papular Rash maculo-papular x x x x x
Hepatic pain Hepatic pain x x x
Tumour pain Tumour pain x x x
Respiratory failure Respiratory failure x x x
Metastatic neoplasm Metastatic carcinoma x
Dyspareunia Dyspareunia x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

topotecan hydrochloride / Hycamtin

Side effects:8
Source:FDA

TOPOTECAN

Side effects:13
Source:FDA Structured Product Label

Topotecan

Side effects:29
Source:BC Cancer

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan

Side effects:40
Source:EMA

topotecan / topotecan hydrochloride

Side effects:40
Source:EMA

TOPOTECAN HYDROCHLORIDE / HYCAMTIN

Side effects:43
Source:FDA

TOPOTECAN

Side effects:47
Source:FDA Structured Product Label

Topotecan hydrochloride / HYCAMTIN POWDER FOR INJECTION

Side effects:47
Source:medicines.org.au

TOPOTECAN (TOPOTECAN HYDROCHLORIDE) / HYCAMTIN

Side effects:49
Source:Health Canada

TOPOTECAN

Side effects:49
Source:FDA Structured Product Label

TOPOTECAN

Side effects:49
Source:FDA Structured Product Label

topotecan

Side effects:49
Source:FDA Structured Product Label

TOPOTECAN

Side effects:50
Source:FDA Structured Product Label

TOPOTECAN

Side effects:50
Source:FDA Structured Product Label

Topotecan

Side effects:75
Source:FDA Structured Product Label

TOPOTECAN

Side effects:80
Source:FDA Structured Product Label

TOPOTECAN

Side effects:81
Source:FDA Structured Product Label

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label